Glaukos Co. (NYSE:GKOS) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. reduced its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 41.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,658 shares of the medical instruments supplier's stock after selling 6,022 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Glaukos were worth $1,298,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. IFP Advisors Inc acquired a new position in Glaukos during the fourth quarter worth $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos in the 4th quarter valued at $90,000. Harvest Fund Management Co. Ltd lifted its stake in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 860 shares in the last quarter. KBC Group NV grew its position in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Finally, EWA LLC acquired a new position in Glaukos in the 3rd quarter valued at about $209,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,744 shares of company stock valued at $2,792,151 in the last ninety days. Insiders own 6.40% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have recently commented on GKOS shares. Mizuho raised shares of Glaukos from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Stephens upgraded Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Truist Financial upped their price target on Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Finally, Needham & Company LLC increased their price target on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $163.25.

Glaukos Stock Performance

Shares of GKOS stock traded up $0.94 during mid-day trading on Friday, hitting $104.14. 1,370,823 shares of the stock were exchanged, compared to its average volume of 797,237. Glaukos Co. has a 12-month low of $84.08 and a 12-month high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of -36.29 and a beta of 1.04. The stock's fifty day simple moving average is $146.88 and its two-hundred day simple moving average is $138.89.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.